Showing 1471-1480 of 1644 results for "".
- Phase 2 Trial of Niflamapimod for Dementia With Lewy Bodies Beginshttps://practicalneurology.com/news/phase-2-trial-of-niflamapimod-for-dementia-with-lewy-bodies-begins-1/2468960/A phase 2 proof-of-concept clinical study, AscenD-LB (NCT04001517) has begun for neflamapimod (EIP Pharma,Cambridge, MA) as a treatment for the cognitive dysfunction associated with dementia with Lewy bodies (DLB). Accounting for appro
- Education May Not Prevent or Slow Cognitive Decline According to Results of a Large-Scale Longitudinal Cohort Studyhttps://practicalneurology.com/news/education-may-not-prevent-or-slow-cognitive-decline-according-to-results-of-a-large-scale-longitudinal-cohort-study/2483014/Education may have a smaller role in slowing cognitive decline and improving brain health than previously thought, according to new study results published in Nature Medicine. Educational attainment was associated with better cognitive performance in later life, higher memory test scores
- Four-Year Clarity-AD Data Show Slower Clinical Decline with Leqembi Treatmenthttps://practicalneurology.com/news/four-year-clarity-ad-data-show-slower-clinical-decline-with-leqembi-treatment/2475914/According to new 48-month data from the Clarity-AD (NCT03887455) open-label extension (OLE) study presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), individuals with early Alzheimer disease (AD) who received continuous treatment with Leqembi (lecanemab-i
- US POINTER Study Results: A Structured Lifestyle Intervention Improved Cognition in Older Adultshttps://practicalneurology.com/news/us-pointer-study-results-a-structured-lifestyle-intervention-improved-cognition-in-older-adults/2475903/Findings from the US POINTER clinical trial (NCT03688126) were presented at the 2025 meeting of the Alzheimer’s Association International Conference (AAIC), demonstrating significant benefits linked to lifestyle interventions for older adults at risk of cognitive decline and dementia. According t
- Intra-Arterial Tenecteplase After Successful Thrombectomy Improves Functional Outcomes in People with Large Vessel Occlusionhttps://practicalneurology.com/news/intra-arterial-tenecteplase-after-successful-thrombectomy-improves-functional-outcomes-in-people-with-large-vessel-occlusion/2475573/Adjunct intra-arterial TNKase (tenecteplase; Genentech, South San Francisco, CA) was associated with significant improvements in 90-day functional outcomes in individuals with acute ischemic stroke due to large vessel occlusion (LVO) presenting 4.5 to 24 hours prior to randomization who had alrea
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- Skin Biopsy Detects Synuclein Pathology in 75% of Those with Idiopathic REM Sleep Behavior Disorderhttps://practicalneurology.com/news/skin-biopsy-detects-synuclein-pathology-in-75-of-those-with-idiopathic-rem-sleep-behavior-disorder/2475314/According to study results presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS), 75% of people with idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD) and no evidence of other neurodegenerative disease tested positive for cutaneous phosphoryla
- Novel Multi-Modal Screening Method for Classification of Narcolepsy Type 1 is Highly Specific and Sensitivehttps://practicalneurology.com/news/novel-multi-modal-screening-method-for-classification-of-narcolepsy-type-1-is-highly-specific-and-sensitive/2475086/Study results presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) demonstrated the specificity and sensitivity of a large-scale screening model for the classification of narcolepsy type 1 (NT1) which integrates polygenic risk scores (PRS), human leukocyte an
- Sunosi Significantly Reduced Excessive Daytime Sleepiness and Obstructive Sleep Apnea Symptoms in Real-World Studyhttps://practicalneurology.com/news/sunosi-significantly-reduced-excessive-daytime-sleepiness-and-obstructive-sleep-apnea-symptoms-in-real-world-study/2475070/The results of a real-world analysis presented at the 2025 Annual Meeting of the Associated Professional Sleep Societies (APSS) show that Sunosi (solriamfetol; Axsome Therapeutics, New York, NY) significantly reduced symptoms of excessive daytime sleepiness (EDS) in individuals with obstructive s
- Gene Therapy for Angelman Syndrome Cleared by FDA for First-in-Human Trialhttps://practicalneurology.com/news/gene-therapy-for-angelman-syndrome-cleared-by-fda-for-first-in-human-trial/2474638/MavriX Bio announced that it has received Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for MVX-220 (MavriX Bio, Middleton, MA), an adeno-associated virus (AAV) gene therapy for Angelman syndrome. MVX-220 is intended to restore neuronal UBE3A gene